Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 12/20 | 0.57 |
| ▸ | MAN2A1 | Q16706 | 10/20 | 0.53 |
| ▸ | MAN2B1 | O00754 | 2/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860576 | 0.83 | MAN1B1 (0.43) | MAN1B1MAN2A1FUCA1OPRM1 | |
| SCHEMBL10353965 | 0.74 | OPRM1 (0.58) | OPRM1ADRB1 | |
| SCHEMBL4956356 | 0.74 | CTSL (0.59) | OPRM1ADRB1 | |
| SCHEMBL19557582 | 0.73 | FUCA1 (0.90) | MAN1B1MAN2A1FUCA1GLA | |
| SCHEMBL15593211 | 0.73 | FUCA1 (0.90) | MAN1B1MAN2A1FUCA1GLA | |
| SCHEMBL15593229 | 0.73 | FUCA1 (0.90) | MAN1B1MAN2A1FUCA1GLA | |
| SCHEMBL19557585 | 0.73 | FUCA1 (0.90) | MAN1B1MAN2A1FUCA1GLA | |
| SCHEMBL2303341 | 0.71 | HDAC3 (0.64) | — | |
| SCHEMBL30426179 | 0.70 | CTSL (0.57) | OPRM1 | |
| SCHEMBL21578194 | 0.69 | MAN1B1 (0.64) | MAN1B1MAN2A1MAN2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | MAN1B1 23/4885MAN2A1 11/4885MAN2B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.